{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:27:45Z","timestamp":1764174465855,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and\/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and\/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28\u20130.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47\u20131.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62\u20130.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.<\/jats:p>","DOI":"10.1038\/s41598-018-20349-6","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T10:35:49Z","timestamp":1516962949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-7343","authenticated-orcid":false,"given":"Gemma","family":"Ib\u00e1\u00f1ez-Sanz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"D\u00edez-Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vilorio-Marqu\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Gracia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Aragon\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Olmedo-Requena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juana","family":"Vid\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Amiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Fern\u00e1ndez-Tard\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Rada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Chirlaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Guin\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"D\u00e1vila-Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Casta\u00f1o-Vinyals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-8214","authenticated-orcid":false,"given":"Beatriz","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Mir\u00f3n-Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trinidad","family":"Dierssen-Sotos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaione","family":"Etxeberria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaia","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"\u00c1lvarez-Cuenllas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manolis","family":"Kogevinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Poll\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"20349_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/j.1572-0241.2008.01875.x","volume":"103","author":"P Hewitson","year":"2008","unstructured":"Hewitson, P., Glasziou, P., Watson, E., Towler, B. & Irwig, L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103, 1541\u20131549 (2008).","journal-title":"Am J Gastroenterol"},{"key":"20349_CR2","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1056\/NEJM200004203421602","volume":"342","author":"DS Alberts","year":"2000","unstructured":"Alberts, D. S. et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 342, 1156\u20131162 (2000).","journal-title":"N Engl J Med"},{"key":"20349_CR3","unstructured":"Force, U. S. P. S. T. Draft Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication, http:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/draft-recommendation-statement\/aspirin-toprevent-cardiovascular-disease-and-cancer (2015)."},{"key":"20349_CR4","doi-asserted-by":"crossref","unstructured":"Chubak, J., Kamineni, A., Buist, D. S. M., Anderson, M. L. & Whitlock, E. P. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force (Agency for Healthcare Research and Quality, Rockville 2015).","DOI":"10.7326\/M15-2117"},{"key":"20349_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10654-014-9971-7","volume":"30","author":"MA Thorat","year":"2015","unstructured":"Thorat, M. A. & Cuzick, J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol 30, 5\u201318 (2015).","journal-title":"Eur J Epidemiol"},{"key":"20349_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7326\/0003-4819-146-5-200703060-00010","volume":"146","author":"A Rostom","year":"2007","unstructured":"Rostom, A. et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146, 376\u2013389 (2007).","journal-title":"Ann Intern Med"},{"key":"20349_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/codi.12838","volume":"17","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Zhang, F. C. & Wang, Y. J. The efficacy and safety of non-steroidal anti-inflammatory drugs in preventing the recurrence of colorectal adenoma: a meta-analysis and systematic review of randomized trials. Colorectal Dis 17, 188\u2013196 (2015).","journal-title":"Colorectal Dis"},{"key":"20349_CR8","doi-asserted-by":"crossref","unstructured":"Thompson, P. A. et al. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J Natl Cancer Inst 108 (2016).","DOI":"10.1093\/jnci\/djw151"},{"key":"20349_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep12044","volume":"5","author":"T Qin","year":"2015","unstructured":"Qin, T. et al. Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials. Sci Rep 5, 12044 (2015).","journal-title":"Sci Rep"},{"key":"20349_CR10","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/ijc.29277","volume":"136","author":"RC Heine-Broring","year":"2015","unstructured":"Heine-Broring, R. C. et al. Dietary supplement use and colorectal cancer risk: a systematic review and meta-analyses of prospective cohort studies. Int J Cancer 136, 2388\u20132401 (2015).","journal-title":"Int J Cancer"},{"key":"20349_CR11","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.3748\/wjg.v22.i18.4594","volume":"22","author":"S Bonovas","year":"2016","unstructured":"Bonovas, S., Fiorino, G., Lytras, T., Malesci, A. & Danese, S. Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. World J Gastroenterol 22, 4594\u20134603 (2016).","journal-title":"World J Gastroenterol"},{"key":"20349_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0434-5","volume":"32","author":"Y Liu","year":"2015","unstructured":"Liu, Y. et al. Vitamin and multiple-vitamin supplement intake and incidence of colorectal cancer: a meta-analysis of cohort studies. Med Oncol 32, 434 (2015).","journal-title":"Med Oncol"},{"key":"20349_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1158\/1055-9965.EPI-09-0038","volume":"18","author":"JA Satia","year":"2009","unstructured":"Satia, J. A., Littman, A., Slatore, C. G., Galanko, J. A. & White, E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev 18, 1419\u20131428 (2009).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"20349_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s10552-013-0192-2","volume":"24","author":"ED Kantor","year":"2013","unstructured":"Kantor, E. D. et al. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control 24, 1137\u20131146 (2013).","journal-title":"Cancer Causes Control"},{"key":"20349_CR15","doi-asserted-by":"crossref","unstructured":"Kantor, E. D. et al. Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow-up study. Int J Cancer, (2016).","DOI":"10.1002\/ijc.30250"},{"key":"20349_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.biocel.2010.03.018","volume":"42","author":"AG Vaiopoulos","year":"2010","unstructured":"Vaiopoulos, A. G., Papachroni, K. K. & Papavassiliou, A. G. Colon carcinogenesis: Learning from NF-kappaB and AP-1. Int J Biochem Cell Biol 42, 1061\u20131065 (2010).","journal-title":"Int J Biochem Cell Biol"},{"key":"20349_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/annrheumdis-2014-206792","volume":"75","author":"MC Hochberg","year":"2016","unstructured":"Hochberg, M. C. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 75, 37\u201344 (2016).","journal-title":"Ann Rheum Dis"},{"key":"20349_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13075-016-1149-0","volume":"18","author":"JP Pelletier","year":"2016","unstructured":"Pelletier, J. P. et al. Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res Ther 18, 256 (2016).","journal-title":"Arthritis Res Ther"},{"key":"20349_CR19","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1136\/ard.2009.120469","volume":"69","author":"AD Sawitzke","year":"2010","unstructured":"Sawitzke, A. D. et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 69, 1459\u20131464 (2010).","journal-title":"Ann Rheum Dis"},{"key":"20349_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.gaceta.2014.12.003","volume":"29","author":"G Castano-Vinyals","year":"2015","unstructured":"Castano-Vinyals, G. et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gac Sanit 29, 308\u2013315 (2015).","journal-title":"Gac Sanit"},{"key":"20349_CR21","doi-asserted-by":"publisher","first-page":"e0117534","DOI":"10.1371\/journal.pone.0117534","volume":"10","author":"SL Navarro","year":"2015","unstructured":"Navarro, S. L. et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One 10, e0117534 (2015).","journal-title":"PLoS One"},{"key":"20349_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lfs.2016.03.028","volume":"152","author":"R Dalirfardouei","year":"2016","unstructured":"Dalirfardouei, R., Karimi, G. & Jamialahmadi, K. Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent. Life Sci 152, 21\u201329 (2016).","journal-title":"Life Sci"},{"key":"20349_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1254\/jjp.85.155","volume":"85","author":"Y Hori","year":"2001","unstructured":"Hori, Y. et al. Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats. Jpn J Pharmacol 85, 155\u2013160 (2001).","journal-title":"Jpn J Pharmacol"},{"key":"20349_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.pharmthera.2014.01.002","volume":"142","author":"P du Souich","year":"2014","unstructured":"du Souich, P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther 142, 362\u2013374 (2014).","journal-title":"Pharmacol Ther"},{"key":"20349_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/aje\/kws186","volume":"176","author":"ED Kantor","year":"2012","unstructured":"Kantor, E. D. et al. Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol 176, 1002\u20131013 (2012).","journal-title":"Am J Epidemiol"},{"key":"20349_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/acm.2013.0323","volume":"20","author":"ED Kantor","year":"2014","unstructured":"Kantor, E. D. et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med 20, 479\u2013485 (2014).","journal-title":"J Altern Complement Med"},{"key":"20349_CR27","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1158\/1055-9965.EPI-13-0470","volume":"22","author":"ED Kantor","year":"2013","unstructured":"Kantor, E. D. et al. Specialty supplement use and biologic measures of oxidative stress and DNA damage. Cancer Epidemiol Biomarkers Prev 22, 2312\u20132322 (2013).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"20349_CR28","unstructured":"Braun, L. & Cohen, M. Herbs and Natural Supplements: An evidence-based guide. Fourth edn, Vol. 2 1379 (Elsevier, 2015)."},{"key":"20349_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(00)03610-2","volume":"357","author":"JY Reginster","year":"2001","unstructured":"Reginster, J. Y. et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357, 251\u2013256 (2001).","journal-title":"Lancet"},{"key":"20349_CR30","unstructured":"Committee, A. D. R. A. in Aust Adverse Drug React Bull Vol. 24 (2005)."},{"key":"20349_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yrtph.2006.07.004","volume":"47","author":"JN Hathcock","year":"2007","unstructured":"Hathcock, J. N. & Shao, A. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol 47, 78\u201383 (2007).","journal-title":"Regul Toxicol Pharmacol"},{"key":"20349_CR32","doi-asserted-by":"crossref","unstructured":"Towheed, T. E. et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev, CD002946 (2005).","DOI":"10.1002\/14651858.CD002946.pub2"},{"key":"20349_CR33","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2165\/00002512-200320140-00004","volume":"20","author":"AJ Matheson","year":"2003","unstructured":"Matheson, A. J. & Perry, C. M. Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging 20, 1041\u20131060 (2003).","journal-title":"Drugs Aging"},{"key":"20349_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10719-016-9665-3","volume":"33","author":"M Bishnoi","year":"2016","unstructured":"Bishnoi, M., Jain, A., Hurkat, P. & Jain, S. K. Chondroitin sulphate: a focus on osteoarthritis. Glycoconj J 33, 693\u2013705 (2016).","journal-title":"Glycoconj J"},{"key":"20349_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/ard.57.11.649","volume":"57","author":"M Urwin","year":"1998","unstructured":"Urwin, M. et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis 57, 649\u2013655 (1998).","journal-title":"Ann Rheum Dis"},{"key":"20349_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"AM Algra","year":"2012","unstructured":"Algra, A. M. & Rothwell, P. M. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13, 518\u2013527 (2012).","journal-title":"Lancet Oncol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20349-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:52:16Z","timestamp":1671587536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-20349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["20349"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-20349-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"3 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Victor Moreno has received consulting fees for Bioiberica, S.A., Barcelona. Bioiberica S.A. has not been involved in the preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2040"}}